LONDON (Alliance News) - FastForward Innovations Ltd said Thursday investee Intensity Therapeutics Inc has been granted fast track designation by the US Food & Drug Administration for its breast cancer drug.
FastForward holds a 2.0% interest in Intensity Therapeutics - a clinical-stage biotechnology firm focused on developing an immune-based approach to treating solid tumour cancers.
Intensity Therapeutics said the fast track designation is for INT230-6, a treatment for patients with relapsed or metastatic triple negative breast cancer who have failed at least two prior lines of therapy, "validates the potential" of the treatment.
"Finding improved therapies for this disease is a critical unmet medical need, and we look forward to working closely with the FDA this year to initiate a Phase 2 clinical study for this indication," said Intensity Therapeutics President & Chief Executive Lewis Bender.
The FDA's fast track program "facilitates development and expedites the review of drugs to treat serious conditions and fill an unmet medical need", said Intensity Therapeutics.
Shares in FastForward Innovations were up 4.1% Thursday at 9.99 pence each.
